Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response

Sebastian Straube, R Andrew Moore, Jocelyn Paine, Sheena Derry, Ceri J Phillips, Ernst Hallier, Henry J McQuay, Sebastian Straube, R Andrew Moore, Jocelyn Paine, Sheena Derry, Ceri J Phillips, Ernst Hallier, Henry J McQuay

Abstract

Background: Clinical trials in chronic pain often collect information about interference with work as answers to component questions of commonly used questionnaires but these data are not normally analysed separately.

Methods: We performed a meta-analysis of individual patient data from four large trials of pregabalin for fibromyalgia lasting 8-14 weeks. We analysed data on interference with work, inferred from answers to component questions of Fibromyalgia Impact Questionnaire (FIQ), Short Form 36 Health Survey, Sheehan Disability Scale, and Multidimensional Assessment of Fatigue, including "How many days in the past week did you miss work, including housework, because of fibromyalgia?" from FIQ. Analyses were performed according to randomised treatment group (pregabalin 150-600 mg daily or placebo), pain improvement (0-10 numerical pain rating scale scores at trial beginning vs. end), and end of trial pain state (100 mm visual analogue pain scale [VAS]).

Results: Comparing treatment group average outcomes revealed modest improvement over the duration of the trials, more so with active treatment than with placebo. For the 'work missed' question from FIQ the change for patients on placebo was from 2.2 (standard deviation [SD] 2.3) days of work lost per week at trial beginning to 1.9 (SD 2.1) days lost at trial end (p < 0.01). For patients on 600 mg pregabalin the change was from 2.1 (SD 2.2) days to 1.6 (SD 2.0) days (p < 0.001). However, the change in days of work lost was substantial in patients with a good pain response: from 2.0 (SD 2.2) days to 0.97 (SD 1.6) days (p < 0.0001) for those experiencing >/= 50% pain improvement and from 1.9 (SD 2.2) days to 0.73 (SD 1.4) days (p < 0.0001) for those achieving a low level of pain at trial end (<30 mm on the VAS). Patients achieving both >/= 50% pain improvement and a pain score <30 mm on the VAS had the largest improvement, from 2.0 (SD 2.2) days to 0.60 (SD 1.3) days (p < 0.0001). Analysing answers to the other questions yielded qualitatively similar results.

Conclusions: Effective pain treatment goes along with benefit regarding work. A reduction in time off work >1 day per week can be achieved in patients with good pain responses.

Trial registration: ClinicalTrials.gov NCT00230776 NCT00333866 NCT00645398.

Figures

Figure 1
Figure 1
Days of work missed. Days of work missed per week at the beginning and end of trials as assessed by the question "How many days in the past week did you miss work, including housework, because of fibromyalgia?" from the Fibromyalgia Impact Questionnaire (FIQ). Data are presented as a comparison of 'state' and 'improvement' responders; 'non-responders' are neither state nor improvement responders; 'double responders' are both. ** p < 0.01, *** p < 0.001, **** p < 0.0001, NS - no significant difference, SD - standard deviation. FIQ data were not available for trial 105, the only trial with a 150 mg pregabalin group. Therefore no data for participants treated with 150 mg pregabalin are presented here.
Figure 2
Figure 2
Interference with work. Interference with work as assessed by the question "When you worked, how much did pain or other fibromyalgia symptoms interfere with your ability to do your work, including housework?" from the Fibromyalgia Impact Questionnaire; responder categories and abbreviations as in Figure 1.

References

    1. McNalley JD, Matheson DA, Bakowshy VS. The epidemiology of self-reported fibromyalgia in Canada. Chronic Dis Can. 2006;27:9–16.
    1. Mas AJ, Carmona L, Valverde M, Ribas B. EPISER Study Group. Prevalence and impact of fibromyalgia on function and quality of life in individuals from the general population: results from a nationwide study in Spain. Clin Exp Rheumatol. 2008;26:519–526.
    1. Bannwarth B, Blotman F, Roué-Le Lay K, Caubère JP, André E, Taïeb C. Fibromyalgia syndrome in the general population of France: A prevalence study. Joint Bone Spine. 2009;76:184–187. doi: 10.1016/j.jbspin.2008.06.002.
    1. Hawley DJ, Wolfe F. Pain, disability, and pain/disability relationships in seven rheumatic disorders: a study of 1,522 patients. J Rheumatol. 1991;18:1552–1557.
    1. Martinez JE, Ferraz MB, Sato EI, Atra E. Fibromyalgia versus rheumatoid arthritis: a longitudinal comparison of the quality of life. J Rheumatol. 1995;22:270–274.
    1. Sprangers MA, de Regt EB, Andries F, van Agt HM, Bijl RV, de Boer JB, Foets M, Hoeymans N, Jacobs AE, Kempen GI, Miedema HS, Tijhuis MA, de Haes HC. Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol. 2000;53:895–907. doi: 10.1016/S0895-4356(00)00204-3.
    1. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US Workforce. JAMA. 2003;290:2443–2454. doi: 10.1001/jama.290.18.2443.
    1. Henriksson CM, Liedberg GM, Gerdle B. Women with fibromyalgia: work and rehabilitation. Disabil Rehabil. 2005;27:685–694. doi: 10.1080/09638280400009089.
    1. Al-Allaf AW. Work disability and health system utilization in patients with fibromyalgia syndrome. J Clin Rheumatol. 2007;13:199–201. doi: 10.1097/RHU.0b013e31812e6b0c.
    1. White KP, Speechley M, Harth M, Ostbye T. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario: the London Fibromyalgia Epidemiology Study. Arthritis Rheum. 1999;42:76–83. doi: 10.1002/1529-0131(199901)42:1<76::AID-ANR10>;2-G.
    1. White AG, Birnbaum HG, Mareva MN, Henckler AE, Grossman P, Mallett DA. Economic burden of illness for employees with painful conditions. J Occup Environ Med. 2005;47:884–892. doi: 10.1097/01.jom.0000172867.29041.eb.
    1. White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med. 2008;50:13–24. doi: 10.1097/JOM.0b013e31815cff4b.
    1. Choy E, Perrot S, Leon T, Kaplan J, Petersel D, Ginovker A, Kramer E. A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Serv Res. 2010;10:102. doi: 10.1186/1472-6963-10-102.
    1. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain. 2010;149:360–364. doi: 10.1016/j.pain.2010.02.039.
    1. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP Jr, LaMoreaux LK, Martin SA, Sharma U. Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–1273. doi: 10.1002/art.20983.
    1. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, Sharma U. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502–514.
    1. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, Martin SA, Barrett JA, Haig G. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792–805. doi: 10.1016/j.jpain.2008.03.013.
    1. Pauer L, Danneskiold-Samsoe B, Jespersen A. Pregabalin for the management of Fibromyalgia (FM): A 14-week, randomised, double-blind, placebo controlled, monotherapy trial (Study A0081100) Ann Rheum Dis. 2008;67(Suppl):256.
    1. Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM, Sharma U. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136:419–431. doi: 10.1016/j.pain.2008.02.027.
    1. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain. 2008;135:217–220. doi: 10.1016/j.pain.2008.01.014.
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. doi: 10.1016/0197-2456(95)00134-4.
    1. Smith LA, Oldman AD, McQuay HJ, Moore RA. Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain. Pain. 2000;86:119–132. doi: 10.1016/S0304-3959(00)00234-7.
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105–121. doi: 10.1016/j.jpain.2007.09.005.
    1. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain. 1997;72:95–97. doi: 10.1016/S0304-3959(97)00005-5.
    1. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson D, Hochberg M, van D, Dougados M. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis. 2005;64:34–37. doi: 10.1136/ard.2004.023028.
    1. Spreadsheet Factory.
    1. QuickCalcs.
    1. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61:277–284. doi: 10.1016/0304-3959(94)00178-H.
    1. Jensen MP, Smith DG, Ehde DM, Robinsin LR. Pain site and the effects of amputation pain: further clarification of the meaning of mild, moderate, and severe pain. Pain. 2001;91:317–322. doi: 10.1016/S0304-3959(00)00459-0.
    1. Turner JA, Franklin G, Heagerty PJ, Wu R, Egan K, Fulton-Kehoe D, Gluck JV, Wickizer TM. The association between pain and disability. Pain. 2004;112:307–314. doi: 10.1016/j.pain.2004.09.010.
    1. Harris RE, Clauw DJ. How do we know that the pain in fibromyalgia is 'real'? Curr Pain Headache Rep. 2006;10:403–407. doi: 10.1007/s11916-006-0069-0.
    1. Napadow V, Lacount L, Park K, As-Sanie S, Clauw DJ, Harris RE. Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity. Arthritis Rheum. 2010;62:2545–2555. doi: 10.1002/art.27497.
    1. Usui C, Hatta K, Doi N, Nakanishi A, Nakamura H, Nishioka K, Arai H. Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin. Arthritis Res Ther. 2010;12:R64. doi: 10.1186/ar2980.
    1. Lachaine J, Beauchemin C, Landry PA. Clinical and economic characteristics of patients with fibromyalgia syndrome. Clin J Pain. 2010;26:284–290. doi: 10.1097/AJP.0b013e3181cf599f.
    1. Rivera J, Esteve-Vives J, Vallejo MA, Rejas J, Grupo ICAF. Factors associated with temporary work disability in patients with fibromyalgia. Rheumatol Int. 2010. in press .
    1. Sallinen M, Kukkurainen ML, Peltokallio L, Mikkelsson M. Women's narratives on experiences of work ability and functioning in fibromyalgia. Musculoskeletal Care. 2010;8:18–26. doi: 10.1002/msc.162.
    1. Löfgren M, Ekholm J, Ohman A. 'A constant struggle': successful strategies of women in work despite fibromyalgia. Disabil Rehabil. 2006;28:447–455. doi: 10.1080/09638280500197891.
    1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600–610. doi: 10.1002/acr.20140.
    1. Phillips C, Main C, Buck R, Aylward M, Wynne-Jones G, Farr A. Prioritising pain in policy making: the need for a whole systems perspective. Health Policy. 2008;88:166–175. doi: 10.1016/j.healthpol.2008.03.008.
    1. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003;114:537–545. doi: 10.1016/S0002-9343(03)00116-5.
    1. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol. 2008;8:29. doi: 10.1186/1471-2377-8-29.
    1. Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 2010;49:706–715. doi: 10.1093/rheumatology/kep432.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe